Treatment patterns by decade of life in elderly women (≥70 years of age) with ovarian cancer

Uyar, Denise; Frasure, Heidi E.; Markman, Maurie; Gruenigen, Vivian E. von

doi:10.1016/j.ygyno.2005.04.037

Cited by 110 publications

(63 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the management of cancer in old patients represents a priority for health care delivery in the immediate future [5]. Many patients are not treated with chemotherapy or, when treated, receive empirically modified schedules or single-agent therapy [12,13]. However, the vast majority of the studies have been performed on women affected by ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy in Elderly Patients with Gynecological Cancer

Palaia¹,

Loprete²,

Musella³

et al. 2013

Oncology

View full text Add to dashboard Cite

Objective: The aim of this study was to determine the tolerability, safety and feasibility of chemotherapy in very elderly patients with gynecological cancers. Methods: We included all patients ≥75 years of age affected by endometrial, ovarian or cervical cancer treated with neoadjuvant, adjuvant or palliative chemotherapy. Data regarding age, stage of the disease, comorbidities, performance status (PS), chemotherapy regimen and dosing, toxicity, treatment delay and dose adjustments were recorded. Results: Forty-nine patients were included in the study. Their median age was 77.5 years. The vast majority of patients (89.8%) presented with advanced neoplastic disease. Twenty-nine of the 49 patients were treated with full-dose chemotherapy; 41% were subjected to the weekly dose. One toxic death was recorded; grade 2 anemia was reported in 8 patients, and grade 2 and 3 neutropenia was recorded in 2 and 3 patients, respectively. Sixty-one percent of the patients completed the planned treatment. Conclusion: Chemotherapy in very elderly patients is feasible with an acceptable toxicity profile. Careful evaluation of PS and assessment of physical and psychological health are necessary to predict tolerability of chemotherapy. A weekly schedule is better tolerated in this setting.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, the vast majority of the studies have been performed on women affected by ovarian cancer. Uyar et al [13] reported their experience with 131 elderly women affected by ovarian cancer subjected to surgery plus chemotherapy. Ninety patients were 70-79 years of age (group 1) and 41 patients were aged ≥80 years (group 2).…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy in Elderly Patients with Gynecological Cancer

Palaia¹,

Loprete²,

Musella³

et al. 2013

Oncology

View full text Add to dashboard Cite

show abstract

“…Gardner reported that the term "elderly" has been variably defined in the ovarian cancer debulking literature as being older than 60, 70, or 80+ years of age. However, most studies determine a cut-off for elderly women as patients aged 70 years or more [4][5][6][7] M A N U S C R I P T…”

Section: Limitations Of Study On Elderly Patientsmentioning

confidence: 99%

“…Recent studies have suggested that elderly patients are less likely to be optimally debulked 3 , receive standard therapy less often [4][5][6] and are less able to tolerate medical treatments 7 . Furthermore, patients over 65 years are rarely included in clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Ovarian cancer in the elderly: Impact of surgery on morbidity and survival

Chéreau

Ballester

Selle

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…Less surgery is being performed in the oldest of old [31][32][33]. Patients receiving neoadjuvant chemotherapy do not always eventually receive surgical debulking [34].…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy Completion in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer—An NRG Oncology/Gynecologic Oncology Group Study

Gruenigen

Huang

Beumer

et al. 2017

Obstetrical &Amp; Gynecological Survey

Self Cite

View full text Add to dashboard Cite

PURPOSE-A simple measure to predict chemotherapy tolerance in elderly patients would be useful. We prospectively tested the association of baseline Instrumental Activities of Daily Living (IADL) score with ability to complete 4 cycles of first line chemotherapy without dose reductions or more than 7 days delay in elderly ovarian cancer patients. RESULTS-Two-hundred-twelve women were enrolled, 152 selecting CP and 60 selecting C. Those who selected CP had higher baseline IADL scores (p<0.001). After adjusting for age and PS, baseline IADL was independently associated with the choice of regimen (p=0.035). The baseline IADL score was not found to be associated with completion of 4 cycles of chemotherapy without dose reduction or delays (p=0.21), but was associated with completion of 4 cycles of chemotherapy regardless of dose reduction and delay (p=0.008) and toxicity, with the odds ratio (OR) of grade 3+ toxicity decreasing 17% (OR: 0.83; 95%CI: 0.72-0.96; p=0.013) for each additional activity in which the patient was independent. After adjustment for chemotherapy regimen, IADL was also associated with overall survival (p=0.019) for patients receiving CP. PATIENTS AND METHODS-PatientsCONCLUSION-Patients with a higher baseline IADL score (more independent) were more likely to complete 4 cycles of chemotherapy and less likely to experience grade 3 or higher toxicity. Keywords chemotherapy; elderly women; ovarian cancer von Gruenigen et al.

show abstract

Treatment patterns by decade of life in elderly women (≥70 years of age) with ovarian cancer

Cited by 110 publications

References 39 publications

Chemotherapy in Elderly Patients with Gynecological Cancer

Chemotherapy in Elderly Patients with Gynecological Cancer

Ovarian cancer in the elderly: Impact of surgery on morbidity and survival

Chemotherapy Completion in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer—An NRG Oncology/Gynecologic Oncology Group Study

Contact Info

Product

Resources

About